Pfizer Inc. has published topline data from the Phase I/II trial of its mRNA-based coronavirus vaccine, showing it produced a strong immune response and no safety concerns in healthy volunteers.
The company is working with German company BioNTech SE on four potential candidates, and presented data from just one of these, BNT162b1, with the data
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?